ENTRADA THERAPEUTICS, INC. Operating Cash Flow
ENTRADA THERAPEUTICS, INC. (TRDA) reported Operating Cash Flow of -$74.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$32.46M.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$41.70M.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$32.20M.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$28.31M.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$128.51M.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$41.56M, a 129.73% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was $139.80M.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$93.79M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$32.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$74.16M 10-Q · filed 2026-08-05 | -$106.36M derived: sum of 3 quarters · filed 2026-08-05 | -$134.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$41.70M 10-Q · filed 2026-05-07 | -$73.90M derived: sum of 2 quarters · filed 2026-05-07 | -$102.21M derived: sum of 3 quarters · filed 2026-05-07 | -$131.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$32.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$60.52M derived: sum of 2 quarters · filed 2026-02-26 | -$90.00M derived: sum of 3 quarters · filed 2026-08-05 | -$128.51M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$28.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$57.80M derived: sum of 2 quarters · filed 2026-08-05 | -$96.31M 10-Q · filed 2025-11-06 | -$127.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$29.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$68.00M 10-Q · filed 2026-08-05 | -$99.60M derived: sum of 3 quarters · filed 2026-08-05 | -$123.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$38.51M 10-Q · filed 2026-05-07 | -$70.11M derived: sum of 2 quarters · filed 2026-05-07 | -$94.38M derived: sum of 3 quarters · filed 2026-05-07 | -$54.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$31.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$55.87M derived: sum of 2 quarters · filed 2026-02-26 | -$16.04M derived: sum of 3 quarters · filed 2026-02-26 | -$41.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$24.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $15.57M derived: sum of 2 quarters · filed 2025-11-06 | -$9.95M 10-Q · filed 2025-11-06 | -$13.96M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $39.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $14.31M 10-Q · filed 2025-08-06 | $10.30M derived: sum of 3 quarters · filed 2025-08-06 | -$14.19M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$25.52M 10-Q · filed 2025-05-08 | -$29.53M derived: sum of 2 quarters · filed 2025-05-08 | -$54.02M derived: sum of 3 quarters · filed 2025-05-08 | -$89.11M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$28.50M derived: sum of 2 quarters · filed 2025-02-27 | -$63.60M derived: sum of 3 quarters · filed 2025-02-27 | $139.80M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$24.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$59.58M derived: sum of 2 quarters · filed 2024-11-05 | $143.82M 10-Q · filed 2024-11-05 | $116.51M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$35.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $168.31M 10-Q · filed 2024-08-13 | $141.00M derived: sum of 3 quarters · filed 2024-08-13 | $113.52M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $203.40M 10-Q · filed 2024-05-07 | $176.09M derived: sum of 2 quarters · filed 2024-05-07 | $148.61M derived: sum of 3 quarters · filed 2024-05-07 | $130.60M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$27.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$54.79M derived: sum of 2 quarters · filed 2024-03-13 | -$72.80M derived: sum of 3 quarters · filed 2024-03-13 | -$93.79M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$27.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$45.49M derived: sum of 2 quarters · filed 2023-11-07 | -$66.48M 10-Q · filed 2023-11-07 | -$87.02M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$18.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$39.00M 10-Q · filed 2023-08-08 | -$59.54M derived: sum of 3 quarters · filed 2023-08-08 | -$73.62M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$20.99M 10-Q · filed 2023-05-10 | -$41.53M derived: sum of 2 quarters · filed 2023-05-10 | -$55.61M derived: sum of 3 quarters · filed 2023-05-10 | -$63.52M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$20.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$34.62M derived: sum of 2 quarters · filed 2023-03-06 | -$42.53M derived: sum of 3 quarters · filed 2023-03-06 | -$50.86M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$14.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$21.98M derived: sum of 2 quarters · filed 2022-11-07 | -$30.32M 10-Q · filed 2022-11-07 | -$36.95M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$16.25M 10-Q · filed 2022-08-11 | -$22.87M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$8.34M 10-Q · filed 2022-05-12 | -$14.96M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$6.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$25.57M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | -$18.95M 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |